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Abstract
Objective—Open radical hysterectomy followed by adjuvant radiation for cervical cancer has 
been associated with significant rates of morbidity. Radical hysterectomy is now often performed 
robotically. We sought to examine if the robotic platform decreased the morbidity associated with 
radical hysterectomy followed by adjuvant radiation.
Methods/Materials—A retrospective cohort of cervical cancer patients undergoing radical 
hysterectomy from 1995-2013 was evaluated. Complications were assessed using electronic record 
review and graded. Chi square tests and Student t-tests were used for analysis.
Results—Overall, 243 patients underwent radical hysterectomy for cervical cancer. Surgical 
approach was 43% open and 57% robotic. Eighty-three patients (34.2%) required adjuvant 
radiation. Overall, radical hysterectomy plus adjuvant radiation was associated with increased risk 
of complication (29%) compared to radical hysterectomy alone (7%) (p<0.001). Complications 
included lymphedema (n=18), bowel-associated complications (n=10), and urinary complications 
(n=7). There was no difference in time to initiation of radiation between open and robotic surgery 
(43 v 47 days, p=0.33). There was no difference in grade 2/3 complications in patients receiving 
adjuvant radiation between open and robotic surgery (27.5% v 27.9%, p=0.97). Patients 
undergoing open surgery followed by radiation experienced a trend towards increased adhesion-
related complications, such as bowel obstruction and ureteral stricture (10 v 2.3%, p=0.19). While 
patients undergoing robotic surgery followed by radiation experienced a trend toward increased 
lymphedema (19 v 8%, p=0.20).
Conclusions—We found no difference in long-term complications between patients who 
underwent robotic as compared to open radical hysterectomy with adjuvant radiation. There may 
be fewer adhesion-related complications with robotic surgery. However, as many radiation related 
complications occur at later time points, continued follow-up to evaluate for potential differences 
between the two groups is necessary.
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Introduction
In 2016 there are estimated to be 12,990 new cases of invasive cervical cancer in the United 
States and 4,120 deaths (1). Over the last 30 years, there has been a significant reduction in 
the number of deaths from cervical cancer, largely due to widespread use of the Pap test. 
Additionally, widespread use of screening allows a large proportion of cervical cancers to be 
diagnosed at an early stage (1).
Determining optimal treatment for stage IB-IIA cervical cancers can be complex. In a 
landmark randomized trial by Landoni et al, the rate of morbidity associated with open 
radical hysterectomy (RH) followed by adjuvant radiation was 28% compared to 12% 
morbidity in women who received primary chemoradiation (2). There was no difference in 
recurrence rate or 5-year overall survival between the two arms. This data has since been 
confirmed in a small cohort with a 24% rate of serious adverse events with RH followed by 
radiation (3). Given the concerns regarding the morbidity of dual modality therapy, primary 
chemoradiation is often preferred in patients whose preoperative evaluation suggests a high 
likelihood of meeting pathologic criteria for postoperative adjuvant radiation, as defined by 
Sedlis et al (4). However, more recently multiple authors have found a survival benefit to RH 
over primary chemoradiation, even in tumors measuring up to 6 cm, further complicating the 
decision for primary treatment (5-7). Furthermore, despite an effort to avoid using both 
radical surgery and adjuvant radiation, some women undergoing RH will ultimately meet 
pathologic criteria for adjuvant radiation on final evaluation.
Recently, the widespread introduction of minimally invasive surgery, specifically robotic 
surgery, has offered an alternative to open RH (8). The use of the robotic platform has 
offered reduction in operative blood loss and increased lymph node counts in type III radical 
hysterectomy for cervical cancer compared to an open approach (9, 10). Additional benefits 
include shorter hospitalization and reduced postoperative complications (9, 11). A key 
advantage of utilizing the robot for RH is to gain the benefits of a minimally invasive 
approach without the steep learning curve and traditionally long operative times seen with 
traditional laparoscopic radical hysterectomy or laparoscopic assisted radical vaginal 
hysterectomy(12).
It is yet to be determined if the use of a minimally invasive approach results in less tissue 
damage and therefore reduced complications when combined with postoperative adjuvant 
radiation. We hypothesized that the combination of RH and adjuvant radiation would be less 
morbid than the combination of open RH and radiation.
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Materials and Methods
Study Design and Setting
Following internal review board approval, a retrospective cohort study of cervical cancer 
patients diagnosed from January 1995 until December 2013 at a single, academic hospital 
was performed. During the study period, 13 different attending surgeons performed open RH 
and 5 different attending surgeons performed robotic RH. All patients underwent RH with 
evaluation of the pelvic lymph nodes in 93% of cases (n=236 had nodal dissection, nodal 
dissection not performed in 3 in the open RH group and 4 in the robot RH group). Inclusion 
criteria were: (1) patients undergoing type III RH for primary treatment of cervical cancer 
and (2) receipt of postoperative adjuvant radiation therapy.
During the study timeframe, standard administration of adjuvant radiation was administered 
to patients who met Sedlis criteria for adjuvant radiation; thus, tumors less than 2cm must 
have had deep third stromal invasion and show lymphovascular space invasion (LVSI). 
Tumors between 2-4cm would need to have middle third stromal invasion and LVSI to 
qualify for adjuvant radiation. Tumors over 4cm with deep or middle third invasion without 
LVSI and tumors over 5cm with superficial third invasion and LVSI would also undergo 
adjuvant radiation(4). Following the publication of GOG 109 in 2000, high-risk patients 
(positive lymph nodes, positive margins, and microscopic parametrial involvement) received 
radio-sensitizing Cisplatin in addition to adjuvant radiation (13). Additionally, GOG 263 
was open at our institution and some patients with intermediate risk pathology were 
randomized to chemoradiation for adjuvant therapy. Finally, during the study timeframe our 
standard administration of adjuvant radiation for patient’s meeting criteria was 3-
dimensional whole pelvic radiation using standard 4 field box technique with shielding of 
normal tissues based on anatomy given at a dose of 180cGy daily for a 4500-5040 cGy.
Outcomes and Variables of Interest
Our primary outcome was postoperative complication. The exposure of interest was mode of 
surgery (open compared to robotic). Data was abstracted from the electronic medical record. 
Complications were defined as urinary complications, bowel complications, and 
lymphedema presenting greater than 30 days after completion of therapy. Complications 
were then graded using the same grading described by Landoni et al with grade 1 
representing mild symptoms not affecting the patient’s health and easily cured, grade 2 
representing symptoms that could be resolved with long term medical therapy, and grade 3 
representing major symptoms requiring surgery or invasive procedures (2). Mode of surgery 
was obtained from the operative report.
Secondary outcomes of interest included time to initiation of postoperative radiation 
treatment in each group, rate of adhesion-related complications (defined as bowel 
obstruction or ureteral stricture), rates of lymphedema, and rates of complication in large 
tumors (defined as >4cm).
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Statistical Methods
This study represents a convenience sample and a de novo power calculation was not 
performed. Students’ t-test was used for continuous variables. Chi square test and Fischer’s 
exact test were used for categorical variables as appropriate. SPSS version 20.0 (IBM Corp: 
Armonk, NY) was used for all analysis.
Results
We identified 243 patients who underwent RH performed by thirteen surgeons. There were 
104 (43%) open RH and 139 (57%) robotic RH during our study period. Median follow up 
was 30 months (interquartile range 10.5-61.1 months). Demographics and operative 
characteristics of the robotic and open arms are summarized in Table 1. There was no 
difference in age, BMI, or operative time between open and robotic cases. Key differences in 
surgical characteristics between the open and robotic arm were higher estimated blood loss 
(462 mL open versus 94mL robotic, p <0.001) and transfusion rate (8% versus 2%, p=0.04) 
in the open arm. Patients in the robotic arm had higher lymph node counts (25 nodes open 
versus 30 nodes robotic, p=0.005). The 30-day surgical complication rate for grade 2 and 3 
complications was significantly increased in the open arm (30% versus 14%, p=0.003).
Of the 243 RH reviewed, 34.2% (n=83) of cases received postoperative adjuvant radiation 
and thus comprised our primary population of interest. There was no difference in need for 
postoperative radiation between the open (n=40, 38.5%) and robot arms (n=43, 31.4%) 
(p=0.25). The median follow up for the robotic arm was shorter at 23 months (range 1-95 
months) compared to 45 months (2-174 months) in the open arm. There was also no 
difference in receipt of chemoradiation (85% versus 77%, p=0.76). Comparison of these two 
populations is summarized in Table 2. There was no difference in the mean time to initiation 
of radiation between open and robot groups (43.2±15.6 days versus 47.3±19.6 days, 
p=0.33). Overall, receipt of postoperative radiation was associated with an increased risk of 
complications (28.9% versus 7.0%, p<0.001). Observed complications included 
lymphedema (n=18), bowel-associated complications (enteritis/proctitis n=8, obstruction 
n=2), and urinary complications (hemorrhagic cystitis n=1, neurogenic bladder n=2, fistula 
n=1, and ureteral stricture n=3).
There was no difference in grade 2/3 complications in patients receiving postoperative 
radiation between the open RH plus radiation and robot RH plus radiation groups (27.5% 
versus 27.9%, p=0.97). There was a trend towards more grade 2/3 lymphedema in the robot 
RH plus radiation group (19%) compared to the open RH plus radiation (9%), p=0.20. 
Patients undergoing open RH experienced a trend towards increased adhesion-related 
complications, such as bowel obstruction and ureteral stricture (10% versus 2.3% p=0.19).
Looking specifically at large tumors (defined as >4cm), there were an equal number of large 
tumors in each group, 28% (n=11) of open RH plus radiation and 28% (n=12) of robot RH 
plus radiation. For large tumors, there was a trend toward fewer grade 2/3 complications in 
the robotic RH plus radiation arm compared to the open RH plus radiation arm (8% versus 
18%, p=0.40).
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Discussion
Nearly 20 years following the publication of the 28% morbidity rate of receiving radical 
surgery followed by adjuvant pelvic radiation, our study confirms this complication rate in a 
similar cohort of patients. We found no difference in complication rate when comparing 
patients undergoing robotic and open radical hysterectomy followed by adjuvant pelvic 
radiation (27.9% versus 27.5%, p=0.97). While we did not find an improvement in the 
complication rate with use of robotic surgery over open surgery, we did note a low 
complication rate in patients receiving surgery alone (7%) compared to patients receiving 
both surgery and radiation (29%). This finding suggests that the morbidity of combination 
treatment in this cohort is largely due to the radiation exposure, rather than the mode of 
surgery. Thus, it is not surprising that no discernable effect of the robotic platform could be 
appreciated.
In evaluating the differences between open and robotic RH, we attempted to focus on areas 
where the robotic platform may offer the greatest benefit. Previous authors have shown that 
postoperative adhesions, and subsequent complications due to adhesions, are significantly 
reduced in patients undergoing minimally invasive simple hysterectomy compared to 
laparotomy. Rates of bowel obstruction following open abdominal hysterectomy have been 
reported at 13.6 per 1,000 hysterectomies with no bowel obstructions following minimally 
invasive hysterectomies (14). We hypothesized there would be a reduction in postoperative 
adhesion-related complications in the robotic group compared to laparotomy. We found that 
10% of open radical hysterectomies had an adhesion related complication compared to 2% 
of robotic cases, but statistical significance was not reached likely due to small sample size 
(p=0.19).
Further, we noted a trend toward increased lymphedema in the robotic RH group (19% 
versus 9%), which is consistent with increased nodal counts in this group. Eight of 12 grade 
2/3 complications in the robotic surgery arm were due to lymphedema. During the study 
time period, all patients at our institution who underwent sentinel lymph node biopsy also 
had completion lymphadenectomy. The use of sentinel nodes in cervical cancer staging 
could reduce this morbidity and ultimately reduce the morbidity seen when combining 
robotic RH and adjuvant radiation.
Since Landoni et al first reported on the significant morbidity seen with combination radical 
hysterectomy and adjuvant radiation(2), minimally invasive surgery has become widely 
adopted due to reductions in blood loss, length of stay, and febrile morbidity (11). 
Additionally, laparoscopic and robotic radical hysterectomies have been shown to have 
equivalent cancer outcomes to when compared to open approaches(15). A concern 
surrounding use of robotic surgery has been related to cost, however, a study in 2012 by 
Wright et al utilizing a large national billing database found a similar cost when comparing 
abdominal radical hysterectomy ($9,618) to laparoscopic radical hysterectomy ($11,774) 
and robotic radical hysterectomy ($10,176)(16). These similar costs in the setting of 
improved surgical morbidity highly favor the use of a minimally invasive approach, 
including robotic surgery, for treatment of early cervical cancers. Furthermore, a cost-
analysis has also shown radical hysterectomy with tailored postoperative radiation to be 
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superior to primary chemoradiation (17). Triaging strategies are needed to further identify 
women preoperatively to allow as many women as possible the potential survival and cost 
benefits of surgical management of their cervical cancer, while avoiding the high morbidity 
of dual therapy.
As with all single-institution, retrospective studies, our study has limitations, which should 
be taken into account when interpreting these findings. We are unable to account for bias 
related to the choice in mode of surgery. Further, our relatively small sample size likely 
limits our ability to detect a statistically significant difference in complication rates between 
the robotic and open groups. Our relatively long follow up period of 30 months does vary 
between arms (23 versus 45 months) and may account for variations in practice as well as 
introduce bias in finding long term complications. Further long-term effects of radiation 
treatment continue to accumulate over time and thus may differ between groups. The 
inclusion of 13 different surgeons helps to improve the variety of surgical care delivered. 
Finally, since the late 1990s there have been significant changes in radiation delivery 
including the use of intensity-modulated radiation therapy (IMRT). IMRT has been 
associated with a reduction in both acute and chronic gastrointestinal, genitourinary, and 
hematologic side effects due to radiation without compromising oncologic outcomes (18). 
Given that IMRT was not used at our institution during the study timeframe, further 
evaluation of the effect of IMRT on complication rates following RH is warranted.
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Table 1
Demographic and clinical characteristics of open and robotic radical hysterectomy
Open radical
hysterectomy,
n=104
Robotic radical
hysterectomy,
n=139
p-value
Age (years) 43.2 (±11.6) 45.5 (±11.3) 0.10
BMI (kg/m2) 30.4 (±6.6) 28.5 (±7.3) 0.50
Operative time (min) 221.4 (±47.5) 213.5 (±51.9) 0.45
Uterine weight (gm) 150 (±134) 133 (±92) 0.32
Estimated blood loss (mL) 462 (±323.5) 94 (±77.4) <0.001
Blood transfusion 8 (8) 3 (2) 0.04
Lymph node count 25 (±13.6) 30 (±13.6) 0.005
30-day complication 31 (30) 20 (14) 0.003
Continuous variables are reported as mean (±standard deviation); Categorical variables are reported as n (%).
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Table 2
Comparing patients undergoing open radical hysterectomy with radiation to robotic radical hysterectomy with 
radiation
Open radical
hysterectomy with
radiation, n=40
Robotic radical
hysterectomy with
radiation, n=43
p-value
Tumor Stage 0.59
  IB1 27 (68) 33 (77)
  IB2 11 (28) 9 (21)
  IIA 2 (5) 1 (2)
Days to initiation of radiation 43.2 (±15.6) 47.3 (±19.6) 0.33
Grade 2/3 complications 11 (27.5) 12 (27.9) 0.97
Grade 2/3 lymphedema 3 (8) 8 (19) 0.20
Adhesion-related complications 4(10) 1 (2) 0.19
Grade 2/3 complication with
tumor >4cm *
2 (18) 1 (8) 0.40
Continuous variables are reported as mean (± standard deviation); Categorical variables are reported as n (%).
*11 open patients had tumor >4cm and 12 robotic patients had tumor >4cm.
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